UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

The oncologist (Dayton, Ohio), 2015-07, Vol.20 (7), p.812-822

2015

Link zum Volltext

Verfügbarkeit prüfen

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

American journal of clinical oncology, 2012-12, Vol.35 (6), p.606-611

2012

Link zum Volltext

Verfügbarkeit prüfen

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001246

2020

Link zum Volltext

Verfügbarkeit prüfen

Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients

Future oncology (London, England), 2024-03, Vol.20 (10), p.579-591

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

Clinical cancer research, 2011-12, Vol.17 (24), p.7765-7775

2011

Link zum Volltext

Verfügbarkeit prüfen

CTIM-17. ADDITIONAL RESULTS FROM A PHASE 1B STUDY OF IGV-001 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v65-v65

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Experimental Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analogue, in Heart Failure

Thyroid (New York, N.Y.), 2002-06, Vol.12 (6), p.527-533

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes

Blood, 2021-11, Vol.138 (Supplement 1), p.1534-1534

2021

Link zum Volltext

Verfügbarkeit prüfen

TIPS-18 TRIAL IN PROGRESS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B STUDY TO ASSESS THE SAFETY AND EFFICACY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGONUCLEOTIDE (IMV-001) TARGETING IGF-1R, IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA

Neuro-oncology advances, 2023-08, Vol.5 (Supplement_3), p.iii38-iii38

2023

Link zum Volltext

Verfügbarkeit prüfen

RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v260-v260

2023

Link zum Volltext

Verfügbarkeit prüfen

Left ventricular performance and remodeling in rabbits after myocardial infarction : effects of a thyroid hormone analogue

Circulation (New York, N.Y.), 1995-02, Vol.91 (3), p.794-801

1995

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT134-CT134

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT171: A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT171-CT171

2023

Link zum Volltext

Verfügbarkeit prüfen

Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction

American journal of physiology. Heart and circulatory physiology, 1997-10, Vol.273 (4), p.H2018-H2029

1997

Link zum Volltext

Verfügbarkeit prüfen

DITPA prevents the blunted contraction-frequency relationship in myocytes from infarcted hearts

American journal of physiology. Heart and circulatory physiology, 2000-03, Vol.278 (3), p.H862-H870

2000

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.10501-10501

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS9105-TPS9105

2013

Link zum Volltext

Verfügbarkeit prüfen

CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS9103-TPS9103

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical experience of a targeted TCR-IL2 fusion protein in combination with cisplatin (CDDP) in patients (pts) with metastatic melanoma

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13088-e13088

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of ALT-801, an interleukin-2/T cell receptor fusion protein targeting p53 (aa264-272)/HLA-A0201 complex, in patients with advanced malignancies

Clinical cancer research, 2011-10, Vol.17 (24), p.7765-7775

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS10099-TPS10099

2012

Link zum Volltext

Verfügbarkeit prüfen

A Rare Case of Endobronchial Amelanotic Melanoma

Journal of thoracic oncology, 2011-03, Vol.6 (3), p.643-644

2011

Link zum Volltext

Verfügbarkeit prüfen

Systemic Toxic Effects Associated With High-Dose Verapamil Infusion and Chemotherapy Administration

JNCI : Journal of the National Cancer Institute, 1991-01, Vol.83 (2), p.105-110

1991

Link zum Volltext

Verfügbarkeit prüfen

Lifestyle Interventions in the Prevention and Treatment of Cancer

American Journal of Lifestyle Medicine, 2009-09, Vol.3 (5), p.337-348

2009

Link zum Volltext

Verfügbarkeit prüfen

Pilot Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analog, in the Treatment of Congestive Heart Failure

Cardiology, 2002-01, Vol.97 (4), p.218-225

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

CTIM-17. ADDITIONAL RESULTS FROM A PHASE 1B STUDY OF IGV-001 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Clinical and Experimental Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analogue, in Heart Failure

Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes

TIPS-18 TRIAL IN PROGRESS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B STUDY TO ASSESS THE SAFETY AND EFFICACY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGONUCLEOTIDE (IMV-001) TARGETING IGF-1R, IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA

RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS

Left ventricular performance and remodeling in rabbits after myocardial infarction : effects of a thyroid hormone analogue

Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs)

Abstract CT171: A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results

Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction

DITPA prevents the blunted contraction-frequency relationship in myocytes from infarcted hearts

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)

A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy

CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM)

Clinical experience of a targeted TCR-IL2 fusion protein in combination with cisplatin (CDDP) in patients (pts) with metastatic melanoma

Phase 1 trial of ALT-801, an interleukin-2/T cell receptor fusion protein targeting p53 (aa264-272)/HLA-A0201 complex, in patients with advanced malignancies

A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS)

A Rare Case of Endobronchial Amelanotic Melanoma

Systemic Toxic Effects Associated With High-Dose Verapamil Infusion and Chemotherapy Administration

Lifestyle Interventions in the Prevention and Treatment of Cancer

Pilot Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analog, in the Treatment of Congestive Heart Failure

Aktive Filter

Suchergebnisse filtern